Albert Lo

Albert Lo has a diverse work experience in the field of cell therapy and stromal biology. Albert is currently employed at BeiGene as a Principal Investigator, specializing in cell therapy. Prior to that, they worked at AbbVie as a Senior Scientist, where they led the development of next-generation T cell therapy, including allogeneic and universal CAR-T. Albert also designed and optimized a mRNA-based screening platform for multi-antigen-targeted CAR-T development.

Before joining AbbVie, Albert Lo served as a Postdoctoral Researcher at Stanford University from 2016 to 2019, focusing on research in the field of cell therapy. Prior to that, they worked at the University of Pennsylvania as a Visiting Scholar and Graduate Student. During their time there, they made significant contributions to the field of stromal biology, immune oncology, and adoptive T-cell therapy. Albert discovered fibroblast activation protein (FAP) as a target for pancreatic cancer metastasis and co-developed the first stromal cell targeted T-cell therapy.

Albert Lo's earlier work experience includes roles as a Research Associate at Academia Sinica, Taiwan, where they conducted research in targeted therapy and phage display, and as a Graduate Student to Research Associate at the same institution, where they focused on phage display and peptide drug conjugates for liver cancer treatment.

Albert Lo completed the Ignite Program for Innovation and Entrepreneurship at Stanford University Graduate School of Business in 2019. Prior to that, they earned a Doctor of Philosophy (PhD) in Cell and Molecular Biology (Gene Therapy and Vaccines Track) at the University of Pennsylvania from 2010 to 2016. Albert also holds a Master of Science (MS) degree in Pathology from National Taiwan University, which they obtained from 2005 to 2007. Albert Lo's undergraduate education includes a Bachelor of Science (BS) degree in Biology/Biological Sciences and Business Administration from National Sun Yat-Sen University from 2000 to 2005.